NPRL2 and Intellectual disability: Baldassari in 201918 reported 83 patients with “language or speech delay” or “intellectual disability” out of 183 (45%), among which 75 had DEPDC5 mutations (48% of total DEPDC5 variant—155), 4 NPRL2 (40% of NPRL2 variants—10), and 4 NPRL3 (4/18, 22% of NPRL3 variants—18).